What is MNOV's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.07B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for MNOV?

P/E (TTM) is n/a and 52-week range is $1.17 to $3.90 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s MNOV figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for MNOV?

The company profile lists revenue (TTM) near $920K, net income (TTM) near $-1.08B, EPS (TTM) near $-0.22 when available from the market-data feed. Figures are informational and may lag live markets.

Where is MediciNova Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in La Jolla, California, US, 49.2M shares outstanding, ISIN US58468P2065 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

MediciNova Inc

$MNOV

Health Care · Biotechnology

IR Run Scenarios

$1.52

-1.30%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

MediciNova, Inc. is a biopharmaceutical company, which focuses on developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus. The company is headquartered in La Jolla, California and currently employs 6 full-time employees. The company went IPO on 2006-12-01. The firm's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

Employees

Website

medicinova.com/

IPO

2006-12-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)